| Authors: |
Drago V; Managing Director, S.C.F. Studio di Consulenza Farmacologica, Catania - Italy., Di Brino E; Altems Advisory, spin-off dell'Università Cattolica del Sacro Cuore, Roma - Italy., Laurita R; Department of Economics and Business Management, Università Cattolica del Sacro Cuore, Milano - Italy., Rumi F; Altems Advisory, spin-off dell'Università Cattolica del Sacro Cuore, Roma - Italy., Basile M; Altems Advisory, spin-off dell'Università Cattolica del Sacro Cuore, Roma - Italy., Pierini A; Access Partnership Lead Integrated Access Management, Roche, Monza - Italy., Ponzianelli A; Director of Market Access & Public Affairs, Moderna, Roma - Italy., Patarnello F; Vice-President Market Access & Government Affairs, AstraZeneca Italia, Milano - Italy., Ianna P; Head of Value Access Oncology, Daiichi Sankyo Italia S.p.A., Milano - Italy., Drago F; Clinical Pharmacology Unit-Regional Pharmacovigilance Centre, University Hospital of Catania, Catania - Italy.; Department of Biomedical and Biotechnological Sciences, University of Catania, Catania - Italy.; Centre for Research and Consultancy in HTA and Drug Regulatory Affairs (CERD), University of Catania, Catania - Italy. |
